Roth Capital Initiates Coverage on Heat Biologics Inc(NASDAQ:HTBX). The shares have been rated Buy. The rating by Roth Capital was issued on Jun 20, 2016.
Heat Biologics Inc (HTBX) shares turned negative on Fridays trading session with the shares closing down -0.09 points or -11.25% at a volume of 13,49,410. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.79. The peak price level was also seen at $0.79 while the days lowest was $0.66. Finally the shares closed at $0.71. The 52-week high of the shares is $7.09 while the 52-week low is $0.401. According to the latest information available, the market cap of the company is $12 M.
Heat Biologics Inc(HTBX) last announced its earnings results on May 11, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.50. Analysts had estimated an EPS of $-0.56.
Several Insider Transactions has been reported to the SEC. On Mar 23, 2016, Michael Kharitonov (director) purchased 900,000 shares at $0.75 per share price.
Heat Biologics Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live genetically-modified irradiated human cells which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens thus harnessing a patient’s own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.